What to Expect of Biogen's (BIIB) Aduhelm Review by Centers For Medicare and Medicaid Services
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Expert Panel Unanimously Decides Biogen's (BIIB) Aduhelm Offers no Patient Benefit
July 15, 2021 5:38 PM EDT(Updated - July 15, 2021 6:00 PM EDT)
Shares of Biogen (NASDAQ: BIIB) are losing 3% after-hours following a unanimous vote by a panel of prominent medical experts claiming the company's recently approved Alzheimer's drug Aduhelm offers no patient benefit.
In a recent meeting held by the... More
